The University of Michigan has been participating as a funded member of the Southwest Oncology Group (SWOG) since January 1, 1980. SWOG participation is an Important component of a large cancer research effort at U of M. We remain committed to the concept that multi-institutional collaboration is essential to the advancement of cancer research. On behalf of the University, Dr. Kenneth Pienta has received the first Team Science Award given by the American Association of Cancer Research (AACR) for the collaborative efforts of teams from the University of Michigan and Brigham and Women's Hospital (Boston, MA). Our goal, as a member institution of SWOG, is to make significant scientific, administrative and patient data contributions to the Group's effort to study and improve cancer therapy. The cooperative group process involves the collection of patient data, adoption of uniform toxicity and response criteria, and conduction of purposeful clinical trials as well as introducing the concept of merging "SPORES" ino the cooperative group mechanism. Cooperative groups have provided the only setting in which the sophisticated concepts of combined modality and adjuvant therapies can be properly Investigated. The cooperative groups have also produced an improved understanding of the Important relatioinships between prognostic factors, therapy and patient survival that could not have been obtained otherwise.
Participation in SWOG is multidisciplinary with membership that clinical and basic research associates involved in group activities. It is characterized by data management and protocol compliance, administrative and scientific contributions, and patient registration contributions. Patient accrual is expected to increase to 15-20 patients per year with increased commitment among SWOG investigators.
|Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8|
|Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7|
|Louie, S G; Ely, B; Lenz, H-J et al. (2013) Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). Br J Cancer 109:1744-9|
|Adelstein, David J; Moon, James; Hanna, Ehab et al. (2010) Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II tria Head Neck 32:221-8|
|Gold, Philip J; Goldman, Bryan; Iqbal, Syma et al. (2010) Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol 5:1472-6|
|Thompson, Ian M (2010) Editorial comment. Urology 75:509-10|
|Rutkowski, Piotr; Van Glabbeke, Martine; Rankin, Cathryn J et al. (2010) Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 28:1772-9|
|Ho, P A; Alonzo, T A; Kopecky, K J et al. (2010) Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia 24:909-13|
|Dorff, Tanya B; Goldman, Bryan; Pinski, Jacek K et al. (2010) Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 16:3028-34|
|Harigopal, Malini; Barlow, William E; Tedeschi, Greg et al. (2010) Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol 176:1639-47|
Showing the most recent 10 out of 130 publications